Research ArticleNuclear Oncology
Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma
Maria Leimer, Amir Kurtaran, Peter Smith-Jones, Markus Raderer, Erst Havlik, Peter Angelberger, Friedrich Vorbeck, Bruno Niederle, Christian Herold and Irene Virgolini
Journal of Nuclear Medicine December 1998, 39 (12) 2090-2094;
Maria Leimer
Amir Kurtaran
Peter Smith-Jones
Markus Raderer
Erst Havlik
Peter Angelberger
Friedrich Vorbeck
Bruno Niederle
Christian Herold


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma
Maria Leimer, Amir Kurtaran, Peter Smith-Jones, Markus Raderer, Erst Havlik, Peter Angelberger, Friedrich Vorbeck, Bruno Niederle, Christian Herold, Irene Virgolini
Journal of Nuclear Medicine Dec 1998, 39 (12) 2090-2094;
Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma
Maria Leimer, Amir Kurtaran, Peter Smith-Jones, Markus Raderer, Erst Havlik, Peter Angelberger, Friedrich Vorbeck, Bruno Niederle, Christian Herold, Irene Virgolini
Journal of Nuclear Medicine Dec 1998, 39 (12) 2090-2094;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- New Advances in Peptide Receptor Radionuclide Therapy
- 111In-DOTA-Lanreotide Scintigraphy in Patients with Tumors of the Lung